The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Su, Chien Wei ^a,b   Chiou, Yu Wei ^a   Tsai, Yi Hsuan ^b   Teng, Ruei Dun ^b   Chau, Gar Yang ^a,b   Lei, Hao Jan ^a,b   Hung, Hung Hsu ^b,c   Huo, Teh Ia ^a,b   Wu, Jaw Ching ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAMMA GLUTAMYLTRANSFERASE; INDOCYANINE GREEN; VIRUS DNA; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE DELETION; GENE MAPPING; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RECURRENT CANCER; RETROSPECTIVE STUDY; SPAIN; TUMOR INVASION; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION; BLOOD; CARCINOMA, HEPATOCELLULAR; GENETICS; HEPATITIS B VIRUS; LIVER NEOPLASMS; MIDDLE AGED; VIROLOGY;

HEPATITIS B VIRUS;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SEQUENCE DELETION; VIRAL LOAD;

EID: 84879256013     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066457     Document Type: Article

References (31)

1. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J, (2012) Management of HCC. J Hepatol 56Suppl: S75-87.
2. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, et al. (2009) Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 51: 890-897.
3. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, et al. (2011) Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 253: 745-758.
4. Choi GH, Park JY, Hwang HK, Kim DH, Kang CM, et al. (2011) Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma. Liver Int 31: 485-493.
5. Fuks D, Dokmak S, Paradis V, Diouf M, Durand F, et al. (2012) Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 55: 132-140.
6. Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, et al. (2011) Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 9: 79-86.
7. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, et al. (2008) Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134: 1908-1916.
8. El-Serag HB, (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273.
9. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73.
10. Kao JH, Chen PJ, Lai MY, Chen DS, (2003) Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124: 327-334.
11. Huang Y, Tong S, Tai AW, Hussain M, Lok AS, (2011) Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology 141: 1412-1421.
12. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, et al. (2008) Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 103: 1663-1673.
13. Colombo M, (2010) Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons. Dig Liver Dis 42Suppl 3: S298-301.
14. Liaw YF, (2010) Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros. Dig Liver Dis 42Suppl 3: S293-297.
15. Locarnini S, Zoulim F, (2010) Molecular genetics of HBV infection. Antivir Ther 15Suppl 3: 3-14.
16. Chisari FV, Ferrari C, (1995) Hepatitis B virus immunopathology. Springer Semin Immunopathol 17: 261-281.
17. Kao JH, Liu CJ, Jow GM, Chen PJ, Chen DS, et al. (2012) Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma. Liver Int 32: 1373.
18. Yeung P, Wong DK, Lai CL, Fung J, Seto WK, et al. (2011) Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis. 203: 646-654.
19. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, et al. (2007) Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 133: 1466-1474.
20. Yeh CT, So M, Ng J, Yang HW, Chang ML, et al. (2010) Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology 52: 1922-1933.
21. Ryu HJ, Kim do Y, Park JY, Chang HY, Lee MH, et al. (2011) Clinical features and prognosis of hepatocellular carcinoma with respect to pre-S deletion and basal core promoter mutations of hepatitis B virus Genotype C2. J Med Virol 83: 2088-2095.
22. Su CW, Lei HJ, Chau GY, Hung HH, Wu JC, et al. (2012) The effect of age on the long-term prognosis of patients with hepatocellular carcinoma after resection surgery: A propensity score matching analysis. Arch Surg 147: 137-144.
23. Edmondson HA, Steiner PE, (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462-503.
24. Neuveut C, Wei Y, Buendia MA, (2010) Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 52: 594-604.
25. Sung WK, Zheng H, Li S, Chen R, Liu X, et al. (2012) Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 44: 765-769.
26. Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, et al. (2011) Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 33: 1104-1112.
27. Chan AC, Chok KS, Yuen WK, Chan SC, Poon RT, et al. (2011) Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 146: 675-681.
28. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, et al. (2012) Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308: 1906-1914.
29. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, et al. (2012) High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142: 1140-1149.
30. Chan HL, Tse CH, Mo F, Koh J, Wong VW, et al. (2008) High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 26: 177-182.
31. Wang LH, Huang W, Lai MD, Su IJ, (2012) Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. Carcinogenesis 33: 466-472.